The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Pertuzumab-Global Market Insights and Sales Trends 2025
Synopsis
Patuzumab is a monoclonal antibody. It was the first monoclonal antibody called an "HER dimerization inhibitor." By binding to HER2, it blocks heterodimerization of HER2 with other HER receptors, slowing tumor growth.
The global Pertuzumab market size is expected to reach US$ 372.4 million by 2029, growing at a CAGR of 5.9% from 2023 to 2029. The market is mainly driven by the significant applications of Pertuzumab in various end use industries. The expanding demands from the Hospital and Medical Center, are propelling Pertuzumab market. Human Source, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Animal Source segment is estimated at % CAGR for the next seven-year period.
Pertuzumab, in combination with trastuzumab, is used in HER2-positive breast cancer treatment. Market trends include its continued use in combination therapies and ongoing clinical trials to explore its potential in other cancer types.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Pertuzumab, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Pertuzumab market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Pertuzumab market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Pertuzumab sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Pertuzumab covered in this report include Novartis AG, Pfizer, Abnova Corporation, InvivoGen, Celltrion, Biocon Limited and Bio-Techne, etc.
The global Pertuzumab market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Novartis AG
Pfizer
Abnova Corporation
InvivoGen
Celltrion
Biocon Limited
Bio-Techne
Global Pertuzumab market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Pertuzumab market, Segment by Type:
Human Source
Animal Source
Global Pertuzumab market, by Application
Hospital
Medical Center
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Pertuzumab manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Pertuzumab in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Patuzumab is a monoclonal antibody. It was the first monoclonal antibody called an "HER dimerization inhibitor." By binding to HER2, it blocks heterodimerization of HER2 with other HER receptors, slowing tumor growth.
The global Pertuzumab market size is expected to reach US$ 372.4 million by 2029, growing at a CAGR of 5.9% from 2023 to 2029. The market is mainly driven by the significant applications of Pertuzumab in various end use industries. The expanding demands from the Hospital and Medical Center, are propelling Pertuzumab market. Human Source, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Animal Source segment is estimated at % CAGR for the next seven-year period.
Pertuzumab, in combination with trastuzumab, is used in HER2-positive breast cancer treatment. Market trends include its continued use in combination therapies and ongoing clinical trials to explore its potential in other cancer types.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Pertuzumab, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Pertuzumab market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Pertuzumab market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Pertuzumab sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Pertuzumab covered in this report include Novartis AG, Pfizer, Abnova Corporation, InvivoGen, Celltrion, Biocon Limited and Bio-Techne, etc.
The global Pertuzumab market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Novartis AG
Pfizer
Abnova Corporation
InvivoGen
Celltrion
Biocon Limited
Bio-Techne
Global Pertuzumab market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Pertuzumab market, Segment by Type:
Human Source
Animal Source
Global Pertuzumab market, by Application
Hospital
Medical Center
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Pertuzumab manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Pertuzumab in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Pertuzumab Market Overview
1.1 Pertuzumab Product Overview
1.2 Pertuzumab Market Segment by Type
1.2.1 Human Source
1.2.2 Animal Source
1.3 Global Pertuzumab Market Size by Type
1.3.1 Global Pertuzumab Market Size Overview by Type (2018-2029)
1.3.2 Global Pertuzumab Historic Market Size Review by Type (2018-2023)
1.3.3 Global Pertuzumab Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Pertuzumab Sales Breakdown by Type (2018-2023)
1.4.2 Europe Pertuzumab Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Pertuzumab Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Pertuzumab Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Pertuzumab Sales Breakdown by Type (2018-2023)
2 Global Pertuzumab Market Competition by Company
2.1 Global Top Players by Pertuzumab Sales (2018-2023)
2.2 Global Top Players by Pertuzumab Revenue (2018-2023)
2.3 Global Top Players by Pertuzumab Price (2018-2023)
2.4 Global Top Manufacturers Pertuzumab Manufacturing Base Distribution, Sales Area, Product Type
2.5 Pertuzumab Market Competitive Situation and Trends
2.5.1 Pertuzumab Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Pertuzumab Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Pertuzumab as of 2022)
2.7 Date of Key Manufacturers Enter into Pertuzumab Market
2.8 Key Manufacturers Pertuzumab Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Pertuzumab Status and Outlook by Region
3.1 Global Pertuzumab Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Pertuzumab Historic Market Size by Region
3.2.1 Global Pertuzumab Sales in Volume by Region (2018-2023)
3.2.2 Global Pertuzumab Sales in Value by Region (2018-2023)
3.2.3 Global Pertuzumab Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Pertuzumab Forecasted Market Size by Region
3.3.1 Global Pertuzumab Sales in Volume by Region (2024-2029)
3.3.2 Global Pertuzumab Sales in Value by Region (2024-2029)
3.3.3 Global Pertuzumab Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Pertuzumab by Application
4.1 Pertuzumab Market Segment by Application
4.1.1 Hospital
4.1.2 Medical Center
4.2 Global Pertuzumab Market Size by Application
4.2.1 Global Pertuzumab Market Size Overview by Application (2018-2029)
4.2.2 Global Pertuzumab Historic Market Size Review by Application (2018-2023)
4.2.3 Global Pertuzumab Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Pertuzumab Sales Breakdown by Application (2018-2023)
4.3.2 Europe Pertuzumab Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Pertuzumab Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Pertuzumab Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Pertuzumab Sales Breakdown by Application (2018-2023)
5 North America Pertuzumab by Country
5.1 North America Pertuzumab Historic Market Size by Country
5.1.1 North America Pertuzumab Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Pertuzumab Sales in Volume by Country (2018-2023)
5.1.3 North America Pertuzumab Sales in Value by Country (2018-2023)
5.2 North America Pertuzumab Forecasted Market Size by Country
5.2.1 North America Pertuzumab Sales in Volume by Country (2024-2029)
5.2.2 North America Pertuzumab Sales in Value by Country (2024-2029)
6 Europe Pertuzumab by Country
6.1 Europe Pertuzumab Historic Market Size by Country
6.1.1 Europe Pertuzumab Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Pertuzumab Sales in Volume by Country (2018-2023)
6.1.3 Europe Pertuzumab Sales in Value by Country (2018-2023)
6.2 Europe Pertuzumab Forecasted Market Size by Country
6.2.1 Europe Pertuzumab Sales in Volume by Country (2024-2029)
6.2.2 Europe Pertuzumab Sales in Value by Country (2024-2029)
7 Asia-Pacific Pertuzumab by Region
7.1 Asia-Pacific Pertuzumab Historic Market Size by Region
7.1.1 Asia-Pacific Pertuzumab Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Pertuzumab Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Pertuzumab Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Pertuzumab Forecasted Market Size by Region
7.2.1 Asia-Pacific Pertuzumab Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Pertuzumab Sales in Value by Region (2024-2029)
8 Latin America Pertuzumab by Country
8.1 Latin America Pertuzumab Historic Market Size by Country
8.1.1 Latin America Pertuzumab Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Pertuzumab Sales in Volume by Country (2018-2023)
8.1.3 Latin America Pertuzumab Sales in Value by Country (2018-2023)
8.2 Latin America Pertuzumab Forecasted Market Size by Country
8.2.1 Latin America Pertuzumab Sales in Volume by Country (2024-2029)
8.2.2 Latin America Pertuzumab Sales in Value by Country (2024-2029)
9 Middle East and Africa Pertuzumab by Country
9.1 Middle East and Africa Pertuzumab Historic Market Size by Country
9.1.1 Middle East and Africa Pertuzumab Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Pertuzumab Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Pertuzumab Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Pertuzumab Forecasted Market Size by Country
9.2.1 Middle East and Africa Pertuzumab Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Pertuzumab Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Novartis AG
10.1.1 Novartis AG Company Information
10.1.2 Novartis AG Introduction and Business Overview
10.1.3 Novartis AG Pertuzumab Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Novartis AG Pertuzumab Products Offered
10.1.5 Novartis AG Recent Development
10.2 Pfizer
10.2.1 Pfizer Company Information
10.2.2 Pfizer Introduction and Business Overview
10.2.3 Pfizer Pertuzumab Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Pfizer Pertuzumab Products Offered
10.2.5 Pfizer Recent Development
10.3 Abnova Corporation
10.3.1 Abnova Corporation Company Information
10.3.2 Abnova Corporation Introduction and Business Overview
10.3.3 Abnova Corporation Pertuzumab Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Abnova Corporation Pertuzumab Products Offered
10.3.5 Abnova Corporation Recent Development
10.4 InvivoGen
10.4.1 InvivoGen Company Information
10.4.2 InvivoGen Introduction and Business Overview
10.4.3 InvivoGen Pertuzumab Sales, Revenue and Gross Margin (2018-2023)
10.4.4 InvivoGen Pertuzumab Products Offered
10.4.5 InvivoGen Recent Development
10.5 Celltrion
10.5.1 Celltrion Company Information
10.5.2 Celltrion Introduction and Business Overview
10.5.3 Celltrion Pertuzumab Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Celltrion Pertuzumab Products Offered
10.5.5 Celltrion Recent Development
10.6 Biocon Limited
10.6.1 Biocon Limited Company Information
10.6.2 Biocon Limited Introduction and Business Overview
10.6.3 Biocon Limited Pertuzumab Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Biocon Limited Pertuzumab Products Offered
10.6.5 Biocon Limited Recent Development
10.7 Bio-Techne
10.7.1 Bio-Techne Company Information
10.7.2 Bio-Techne Introduction and Business Overview
10.7.3 Bio-Techne Pertuzumab Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Bio-Techne Pertuzumab Products Offered
10.7.5 Bio-Techne Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Pertuzumab Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Pertuzumab Industrial Chain Analysis
11.4 Pertuzumab Market Dynamics
11.4.1 Pertuzumab Industry Trends
11.4.2 Pertuzumab Market Drivers
11.4.3 Pertuzumab Market Challenges
11.4.4 Pertuzumab Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Pertuzumab Distributors
12.3 Pertuzumab Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
